Clinical trial
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
NCT00005057 · National Human Genome Research Institute (NHGRI), NIH · Completed
Key facts
| NCT number | NCT00005057 |
|---|---|
| Title | Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma |
| Official title | A Phase I Study of Intralesional Administration of an Adenovirus Vector Expressing the HSV-1 Thymidine Kinase Gene (AdV.RSV-TK) in Combination With Escalating Doses of Ganciclovir in Patients With Cutaneous Metastatic Malignant Melanoma |
| Lead sponsor | National Human Genome Research Institute (NHGRI), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | adenovirus RSV-TK, ganciclovir |
| Start date | Mar 1, 2000 |
| First posted | Aug 9, 2004 |
| Last update posted | Apr 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: